Faecalibacteriumprausnitzii Is Associated With Clinical Response to Immune Checkpoint Inhibitors in Patients With Advanced Gastric Adenocarcinoma: Results of Microbiota Analysis of PRODIGE 59-FFCD 1707-DURIGAST Trial.
ANNÉE
2024
AUTEURS
Bredon M, le Malicot K, Louvet C, Evesque L, Gonzalez D, Tougeron D, Sokol H.
CONGRÈS/REVUE
Gastroenterology
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES